Research Progress on the Relationship between CD36 Antigen Deficiency and Clinical Blood Transfusion Safety

doi:10.3969/j.issn.1671-2587.2026.02.021

JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE ›› 2026, Vol. 28 ›› Issue (2): 279-285.DOI: 10.3969/j.issn.1671-2587.2026.02.021

Previous Articles Next Articles

Research Progress on the Relationship between CD36 Antigen Deficiency and Clinical Blood Transfusion Safety

WANG Xin, LI Yao, SHAN Zhuoyue, ZHAO Liyan

The Second Hospital of Jilin University, Changchun 130041

Received:2025-09-17 Accepted:2025-10-28 Online:2026-04-20 Published:2026-04-22

Abstract

Abstract: The CD36 antigen is widely present on the surface of platelets, monocytes and other cells. However, some individuals in the population show a deficiency of the CD36 antigen. These individuals may produce anti-CD36 antibodies after exposure to immune stimuli such as blood transfusion and pregnancy. Patients carrying this antibody may experience complications related to blood transfusion, such as platelet transfusion refractoriness, alloimmune thrombocytopenia in the fetus and neonate, and post-transfusion purpura, if they receive blood products positive for the CD36 antigen again. This poses a threat to the safety of clinical blood transfusion. This article will review the molecular basis of CD36 antigen deficiency and its correlation with platelet transfusion refractoriness, alloimmune thrombocytopenia in the fetus and neonate, and transfusion-related acute lung injury.

Key words: CD36 antigen deficiency, Platelet transfusion refractoriness, Fetal and neonatal alloimmune thrombocytopenia, Transfusion-related acute lung injury, Post-transfusion purpura

CLC Number:

R457.1

WANG Xin, LI Yao, SHAN Zhuoyue, ZHAO Liyan. Research Progress on the Relationship between CD36 Antigen Deficiency and Clinical Blood Transfusion Safety[J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2026, 28(2): 279-285.

References

[1] Wang J C,Li Y S.CD36 tango in cancer: signaling pathways and functions[J]. Theranostics,2019,9(17): 4893-4908.
[2] Shu H Y,Peng Y Z,Hang W J,et al.The role of CD36 in cardiovascular disease[J]. Cardiovasc Res,2022, 118(1):115-129.
[3] Zhang X D,Fan J H,Li H P,et al.CD36 signaling in diabetic cardiomyopathy[J]. Aging Dis,2021,12(3):826-840.
[4] Yang X C,Okamura D M,Lu X F,et al.CD36 in chronic kidney disease: novel insights and therapeutic opportunities[J]. Nat Rev Nephrol,2017,13(12):769-781.
[5] Yang Y X,Liu X K,Yang D,et al.Interplay of CD36, autophagy,and lipid metabolism: insights into cancer progression[J]. Metabolism,2024,155:155905.
[6] Li Y X,Huang X G,Yang G,et al.CD36 favours fat sensing and transport to govern lipid metabolism[J]. Prog Lipid Res,2022,88:101193.
[7] Smith J,Su X,El-Maghrabi R,et al.Opposite regulation of CD36 ubiquitination by fatty acids and insulin: effects on fatty acid uptake[J]. J Biol Chem,2008,283(20): 13578-13585.
[8] Jiang M Z,Wu N,Xu B,et al.Fatty acid-induced CD36 expression via O-GlcNAcylation drives gastric cancer metastasis[J]. Theranostics,2019,9(18):5359-5373.
[9] Osz K,Russ M,Petrik J.The thrombospondin-1 receptor CD36 is an important mediator of ovarian angiogenesis and folliculogenesis[J]. Reprod Biol Endocrinol,2014, 12:21.
[10] 廖信志. CD36促进肾透明细胞癌血管生成的研究[D].赣南医学院,2023.
[11] 周映君,韦喜敢,周吉成,等. CD36抗原缺失与血小板输注无效关系的研究进展[J]. 临床血液学杂志,2016,29(10): 851-854.
[12] Kashiwagi H,Tomiyama Y,Nozaki S,et al.Analyses of genetic abnormalities in type I CD36 deficiency in Japan: identification and cell biological characterization of two novel mutations that cause CD36 deficiency in man[J]. Hum Genet,2001,108(6): 459-466.
[13] Lee K,Godeau B,Fromont P,et al.CD36 deficiency is frequent and can cause platelet immunization in Africans[J]. Transfusion,1999,39(8):873-879.
[14] Flesch B K,Scherer V,Opitz A,et al.Platelet CD36 deficiency is present in 2.6% of Arabian individuals and can cause NAIT and platelet refractoriness[J]. Transfusion, 2021,61(6):1932-1942.
[15] Yanai H,Chiba H,Fujiwara H,et al.Phenotype-genotype correlation in CD36 deficiency types Ⅰ and Ⅱ[J]. Thromb Haemost,2000,84(3):436-441.
[16] Phuangtham R,Santoso S,Leelayuwat C,et al.Frequency of CD36 deficiency in Thais analyzed by quantification of CD36 on cell surfaces and in plasma[J]. Transfusion, 2020,60(4):847-854.
[17] Liu J,Shao Y,Ding H Q,et al.Distribution of CD36 deficiency in different Chinese ethnic groups[J]. Hum Immunol,2020,81(7):366-371.
[18] 蔡碧红,王嘉励,叶欣,等. 广州地区无偿献血者CD36缺失频率及血小板输注治疗[J]. 实用医学杂志,2020, 36(12):1634-1637.
[19] Lyu Q L,Peng M Z,Chen Q,et al.Frequency and molecular basis of CD36 deficiency among platelet donors in Kunming,China[J]. Platelets,2023,34(1): 2176168.
[20] Wang W,Yan Z,Hu J,et al.Scavenger receptor class B,type 1 facilitates cellular fatty acid uptake[J]. Biochim Biophys Acta Mol Cell Biol Lipids,2020,1865(2):158554.
[21] 王超,吕蓉,胡晓玉,等.CD36抗原缺失Ⅰ型4种碱基突变及蛋白结构生物信息学分析[J].临床输血与检验,2024, 26(6):726-735.
[22] Xu X G,Liu Y,Hong X Z,et al.Variants of CD36 gene and their association with CD36 protein expression in platelets[J]. Blood Transfus,2014,12(4):557-564.
[23] Kashiwagi H,Tomiyama Y,Kosugi S,et al.Family studies of type Ⅱ CD36 deficient subjects: linkage of a CD36 allele to a platelet-specific mRNA expression defect(s) causing type Ⅱ CD36 deficiency[J]. Thromb Haemost, 1995,74(2):758-763.
[24] Lyu Q L,Lin Y W,Pan Y M,et al.The polymorphism analysis for CD36 among platelet donors[J]. Sci Rep, 2024,14(1):8534.
[25] 林凤秋,李晓丰,李剑平. 血小板CD36抗原Ⅱ型缺失与内含子序列多态性的相关性[J]. 中国输血杂志,2022,35(8): 791-795.
[26] Tasaki T,Fujii K,Gotoh K,et al.Pre-transfusion screening for platelet-reactive antibodies[J]. Transfus Apher Sci,2005,33(2):157-164.
[27] Xu X Z,Chen D W,Ye X,et al.Improvement of anti-CD36 antibody detection via monoclonal antibody immobilization of platelet antigens assay by using selected monoclonal antibodies[J]. Ann Lab Med,2023, 43(1):86-91.
[28] Chen X Y,Zhao Y H,Lv Y,et al.Immunological platelet transfusion refractoriness: current insights from mechanisms to therapeutics[J]. Platelets,2024,35(1): 2306983.
[29] Ikeda H,Mitani T,Ohnuma M,et al.A new platelet-specific antigen,Naka,involved in the refractoriness of HLA-matched platelet transfusion[J]. Vox Sang,1989, 57(3):213-217.
[30] 周助人,李剑平. CD36基因缺失与同种免疫性血小板减少症关系的研究进展[J]. 吉林大学学报(医学版),2012, 38(6):1232-1235.
[31] Pedini P,Hicheri Y,Bertand G,et al.A case of platelet transfusion refractoriness in a CD36-negative patient with acute myeloid leukemia: Diagnostic and therapeutic management[J]. Transfusion,2022,62(10): 2148-2150.
[32] Sekayan T,Allen E S,Kopko P,et al.Management challenge of a rare concomitant platelet glycoprotein IV/CD36 and IIb/IIIa deficiencies: Case illustration[J]. Transfusion,2025,65(4):767-772.
[33] Morishita K,Wakamoto S,Miyazaki T,et al.Life-threatening adverse reaction followed by thrombocytopenia after passive transfusion of fresh frozen plasma containing anti-CD36 (Nak) isoantibody[J]. Transfusion,2005,45(5): 803-806.
[34] Wakamoto S,Fujihara M,Urushibara N,et al.Heterogeneity of platelet responsiveness to anti-CD36 in plasma associated with adverse transfusion reactions[J]. Vox Sang,2005,88(1):41-51.
[35] 周燕,钟周琳,卢芳,等. 产妇抗CD36抗体发生率及诱导血小板凋亡的实验研究[J]. 临床血液学杂志,2021,34(8): 531-535.
[36] Cohn C S.Platelet transfusion refractoriness: how do I diagnose and manage?[J]. Hematology Am Soc Hematol Educ Program,2020,2020(1):527-532.
[37] 中国输血协会人类组织抗原专业委员会,中国输血协会免疫血液学专业委员会. 免疫性血小板输注无效的判定及临床实践专家共识[J]. 临床输血与检验,2022,24(3): 273-278.
[38] 何子毅,胡应明,贝孟辉,等. 东莞地区CD36抗原缺失型血小板献血者资料库的建立与分析[J]. 临床输血与检验, 2025,27(4):492-498.
[39] 毛伟,蒋玉林,朱传福,等. 国内血小板基因库建设及应用的现状研究[J]. 临床输血与检验,2024,26(5):656-661.
[40] 徐筠娉,熊镗睿,杨帆,等. CD36抗原表达大规模筛查及阴性供者结构与供能分析[J]. 中国输血杂志,2025,38(5): 615-620.
[41] 朱发明,毛伟,张志欣. 血小板配合性输注的分析和展望[J]. 中国输血杂志,2022,35(11):1097-1100.
[42] Al-Samkari H,Kuter D J.Immune thrombocytopenia in adults: modern approaches to diagnosis and treatment[J]. Semin Thromb Hemost,2020,46(3):275-288.
[43] 赵沛喆,徐熠,梁雅珺,等. 免疫性血小板输注无效预防策略研究进展[J]. 中国输血杂志,2025,38(3):448-454.
[44] Xu X Z,Li L,Xia W J,et al.Successful management of a hydropic fetus with severe Anemia and thrombocytopenia caused by anti-CD36 antibody[J]. Int J Hematol,2018,107(2):251-256.
[45] Xu X Z,Chen D W,Ye X,et al.Successful prenatal therapy for anti-CD36-mediated severe FNAIT by deglycosylated antibodies in a novel murine model[J]. Blood,2021,138(18):1757-1767.
[46] 唐颖怡,陈大伟,夏文杰,等. CD36抗体引起的胎儿新生儿同种免疫性血小板减少症中人脐静脉内皮细胞通透性作用机理的初步研究[J]. 中国输血杂志,2023,36(9):766-770.
[47] 谢文举,付子可,王秋实. 胎儿/新生儿同种免疫性血小板减少症研究进展[J]. 临床输血与检验,2025,27(6):882-888.
[48] 魏亚明,桂嵘,王秋实,等. 血小板抗体检测专家共识[J]. 临床输血与检验,2020,22(1):1-5.
[49] Semple J W,Rebetz J,Kapur R.Transfusion-associated circulatory overload and transfusion-related acute lung injury[J]. Blood,2019,133(17):1840-1853.
[50] Nakajima F,Nishimura M,Hashimoto S,et al.Role of anti-Nak(a) antibody,monocytes and platelets in the development of transfusion-related acute lung injury[J]. Vox Sang,2008,95(4):318-323.
[51] Chen D W,Kang T,Xu X Z,et al.Mechanism and intervention of murine transfusion-related acute lung injury caused by anti-CD36 antibodies[J]. JCI Insight, 2023,8(6):e165142.
[52] 吴泳彬. 抗CD36抗体诱导的小鼠TRALI模型建立及初步机制探讨[D]. 广州:南方医科大学,2020.
[53] 刘晓敏,江颖,刘俊婷,等. 中国人群输血相关急性肺损伤58例文献回顾性分析[J]. 中国输血杂志,2020,33(8): 780-783.
[54] 胡嫒,陈唯韫,黄宇光. 输血相关急性肺损伤发病机制及防治措施研究进展[J]. 中国医学科学院学报,2020,42(5): 674-680.
[55] 范玥,张明燃,梁思敏. 输血相关急性肺损伤2例[J]. 现代临床医学,2024,50(5):340-341.
[56] Padhi P,Parihar G S,Stepp J,et al.Post-transfusion Purpura: a rare and life-threatening aetiology of thrombocytopenia[J]. BMJ Case Rep,2013,2013: bcr2013008860.
[57] Wu G G.Detection of clinically relevant platelet antibodies in the Asian population[J]. ISBT Sci Ser, 2014,9(1):112-117.
[58] Li L L,Zhong Z L,Zhou Y,et al.Platelet donor database: a study on the specialist donor database for the patients with alloimmune thrombocytopenia in the Chinese population and the assessment of completeness[J]. Chin Med J,2021,135(2):234-236.
[59] Bierling P,Godeau B,Fromont P,et al.Posttransfusion Purpura-like syndrome associated with CD36 (Naka) isoimmunization[J]. Transfusion,1995, 35(9):777-782.
[60] Hawkins J,Aster R H,Curtis B R.Post-transfusion Purpura: current perspectives[J]. J Blood Med,2019,10: 405-415.
[61] 徐秀章,陈大伟,夏文杰,等. CD36单克隆抗体体内清除血小板的机制探讨[J]. 临床输血与检验,2025,27(1):48-53.
[62] 贺雪花,乔佳佳,郭效君,等. CD36抗原缺失与输血相关免疫的研究进展[J]. 中国输血杂志,2021,34(12):1408-1411.

Research Progress on the Relationship between CD36 Antigen Deficiency and Clinical Blood Transfusion Safety

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 11

Recommended Articles

Metrics

Comments

About

Author

Journal

Access Statistics

Contact

[1]	LIU Wen, WANG Wenxing, FAN Na, CHEN Wei, LIANG Jing. Imbalance between Th17/Treg Cells and Associated Cytokines in Patients with Platelet Transfusion Refractoriness [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2026, 28(1): 65-69.
[2]	XIE Wenju, FU Zike, WANG Qiushi. Progress in Fetal and Neonatal Alloimmune Thrombocytopenia [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2025, 27(6): 882-888.
[3]	CAI Yin, CHEN Zhiying, JIANG Ling, REN Yana, ZHENG Lan, ZHOU Guoping. Screening Analysis of HLA Antibodies of Blood Donors in Shanghai Area [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2024, 26(6): 777-780.
[4]	GAO Li, YANG Yiming, JIANG Xueyu, XIE Rufeng, SUN Juan, YANG Jie. The Infusion of Extracellular Vesicle Secreted by Allogeneic Tolerant Dendritic Cells Carries the Risk of Exacerbating TRALI [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2024, 26(5): 592-596.
[5]	FAN Chengyan, WEN Yujie, LIAN Xue, ZHANG Dan, WANG Jie, JING Yuanyuan, WANG Lijun, LI Wei, JIA Yanjun, LI Dongmei. Changes in Serum Platelet-related Antibodies in Patients with Immune Platelet Transfusion Refractoriness and Clinical Significance [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2024, 26(5): 661-666.
[6]	WEN Yujie, FAN Chengyan, ZHANG Dan, LI Dongmei, SUN Tiecheng, JIA Yanjun, LIU Na. Platelet Transfusion Refractoriness: Understanding the Clinical Significance of Platelet Autoantibodies [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2024, 26(4): 511-515.
[7]	FAN Chengyan, WEN Yujie, ZHANG Dan, LIAN Xue, LIU Na, SUN Tiecheng, WANG Dongmei, JIA Yanjun, LI Dongmei. Analysis of HLA/HPA Antibody Specificity and Its Impact on Platelet Transfusion Outcomes in Patients with Immune Platelet Transfusion Refractoriness [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2024, 26(3): 353-358.
[8]	LIU Zheng, SUN Yamin, SHAO Shujun, et al. Analysis of HLA-I Antibody Specificity in Patients with Platelet Transfusion Refractoriness [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2023, 25(5): 631-635.
[9]	JING Yuan-yuan, WANG Jie, LI Dong-mei, et al. Factors Influencing Development of HLA and/or HPA Antibodies in Patients with Platelet Refractoriness [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2021, 23(6): 723-727.
[10]	LI Dong-mei, WANG Jie, JING Yuan-yuan, et al. Clinical Significance of C1q-HLA Antibody in Patient Refractory to Platelet Transfusion [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2020, 22(2): 126-130.
[11]	WANG Gui-qiang, LIN Xin-mei, FENG Jun-jian, et al. The Role of Serum Kerbs Von Lungren 6 Antigen（KL-6） in Transfusion-related Acute Lung Injury [J]. JOURNAL OF CLINICAL TRANSFUSION AND LABORATORY MEDICINE, 2019, 21(5): 449-453.